Sartorius_May21_NeutAntiMakingTheir - 39


Wu et al. reported the generation and testing of

interface according to the crystallographic

single- domain antibodies targeting SARS CoV-2

structure of the SARS-CoV-2 S receptor-ACE2

RBD 13. The panning using SARS-CoV-2 RBD and

protein complex 15.

S1 as antigens resulted in the identification of

Octet® BLI was utilized to the test target

antibodies targeting five types of neutralizing or

specificity of the peptide binding to SARS CoV-2

non-neutralizing epitopes on SARS-CoV-2 RBD.

RBD. SPB1 bound the RBD with an affinity of 47

They tested 18 human single-domain antibodies

nM (kon = 4.69 × 104 M-1 s-1 and koff = 2.2 × 10-3

in competition binding assays using the Octet®

s-1 ) where this binding affinity is comparable

system and found that they could be divided into

to that of the full-length ACE2 binding to SARS

three competition groups (groups A, B, or C) that

CoV-2 RBD. SBP1 could, therefore, potentially

did not show any competition with each other.

cover spike proteins on the SARS-CoV-2 Surface

The single domain antibody n3130 identified from

and outcompete the binding for ACE2 as a novel

the library using SARS-CoV-2 S1 as the panning

therapeutic intervention strategy.

antigen showed potent neutralization activity
with both pseudotyped and live virus and strong


binding to SARS CoV-2 S1 and RBD domains.

Affinity characterization, neutralization and

This work also reports the unique immunogenic

competition studies are essential in the selection

profiles of SARS-CoV-2 RBD compared to that

of high affinity and potentially neutralizing

of SARS-CoV and MERS-CoV, which may have

lead candidates for therapeutic and vaccine

important implications for the development of

development against the novel SARS CoV-2.

effective vaccines against SARS CoV-2.

Kinetic analysis further describes the components
of association and dissociation that comprise the

Design and Validation of a Peptide

overall affinity, while cross-competition assays

Inhibitor to Block Viral Entry

allow for the identification of more optimal

In addition to protective antibodies, peptide


and small molecule inhibitors can also be used

In addition to the studies illustrated above,

as viable inhibitory strategies to target the SARS

researchers have also utilized Octet® assays to

CoV-2 RBD to prevent virus entry. Zhang et al.

characterize and investigate other members of

investigated the design and development of a

the coronavirus or associated species where the

23-mer peptide inhibitor (SBP1) discovered based

observations and results are invaluable towards

on the ACE2 PD α1 helix that spans the binding

implementing and framing current therapeutic

| 39


Table of Contents for the Digital Edition of Sartorius_May21_NeutAntiMakingTheir

Sartorius_May21_NeutAntiMakingTheir - 1
Sartorius_May21_NeutAntiMakingTheir - 2
Sartorius_May21_NeutAntiMakingTheir - 3
Sartorius_May21_NeutAntiMakingTheir - Contents
Sartorius_May21_NeutAntiMakingTheir - 5
Sartorius_May21_NeutAntiMakingTheir - 6
Sartorius_May21_NeutAntiMakingTheir - 7
Sartorius_May21_NeutAntiMakingTheir - 8
Sartorius_May21_NeutAntiMakingTheir - 9
Sartorius_May21_NeutAntiMakingTheir - 10
Sartorius_May21_NeutAntiMakingTheir - 11
Sartorius_May21_NeutAntiMakingTheir - 12
Sartorius_May21_NeutAntiMakingTheir - 13
Sartorius_May21_NeutAntiMakingTheir - 14
Sartorius_May21_NeutAntiMakingTheir - 15
Sartorius_May21_NeutAntiMakingTheir - 16
Sartorius_May21_NeutAntiMakingTheir - 17
Sartorius_May21_NeutAntiMakingTheir - 18
Sartorius_May21_NeutAntiMakingTheir - 19
Sartorius_May21_NeutAntiMakingTheir - 20
Sartorius_May21_NeutAntiMakingTheir - 21
Sartorius_May21_NeutAntiMakingTheir - 22
Sartorius_May21_NeutAntiMakingTheir - 23
Sartorius_May21_NeutAntiMakingTheir - 24
Sartorius_May21_NeutAntiMakingTheir - 25
Sartorius_May21_NeutAntiMakingTheir - 26
Sartorius_May21_NeutAntiMakingTheir - 27
Sartorius_May21_NeutAntiMakingTheir - 28
Sartorius_May21_NeutAntiMakingTheir - 29
Sartorius_May21_NeutAntiMakingTheir - 30
Sartorius_May21_NeutAntiMakingTheir - 31
Sartorius_May21_NeutAntiMakingTheir - 32
Sartorius_May21_NeutAntiMakingTheir - 33
Sartorius_May21_NeutAntiMakingTheir - 34
Sartorius_May21_NeutAntiMakingTheir - 35
Sartorius_May21_NeutAntiMakingTheir - 36
Sartorius_May21_NeutAntiMakingTheir - 37
Sartorius_May21_NeutAntiMakingTheir - 38
Sartorius_May21_NeutAntiMakingTheir - 39
Sartorius_May21_NeutAntiMakingTheir - 40
Sartorius_May21_NeutAntiMakingTheir - 41
Sartorius_May21_NeutAntiMakingTheir - 42